JOHN KENNETH ROSE
Pilots at Vineyard Pt Rd, Guilford, CT
License number
Connecticut A2889551
Issued Date
Aug 2015
Expiration Date
Aug 2017
Category
Airmen
Type
Authorized Aircraft Instructor
Address
Address
445 Vineyard Point Rd, Guilford, CT 06437
Professional information
Methods For Making Modified Recombinant Vesiculoviruses
US Patent:
6168943, Jan 2, 2001
Filed:
May 3, 1996
Appl. No.:
8/646695
Inventors:
John K. Rose - Guilford CT
Assignee:
Yale University - New Haven CT
International Classification:
A61K 39205, C07H 2104, C07K 14145, C12N 701
US Classification:
435239
Abstract:
The invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.
Liposomal Transfection Of Nucleic Acids Into Animal Cells
US Patent:
5279833, Jan 18, 1994
Filed:
Apr 4, 1990
Appl. No.:
7/504498
Inventors:
John K. Rose - Guilford CT
Assignee:
Yale University - New Haven CT
International Classification:
A61K 3722, C07H 2102, C07H 2104
US Classification:
424450
Abstract:
A reagent for introducing a nucleic acid into an animal cell. The reagent comprises (a) a neutral lipid such as dioleoylphosphatidylethanolamine and (b) a cationic lipid selected from the group consisting of an ammonium salt such as dimethyldioctadecylammonium bromide or cetyldimethylethylammonium bromide, an amine such as stearylamine, and a benzethonium salt such as methylbenzethonium chloride.
Recombinant Vesiculoviruses And Their Uses
US Patent:
7153510, Dec 26, 2006
Filed:
May 4, 1995
Appl. No.:
08/435032
Inventors:
John K. Rose - Guilford CT, US
Assignee:
Yale University - New Haven CT
International Classification:
A61K 39/12, C12Q 1/70
US Classification:
4241991, 4242241, 435 5, 435 693, 4351723, 4352351, 435236, 435239, 4352402, 4353201
Abstract:
The invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.
Rhabdoviruses With Reengineered Coats
US Patent:
7081243, Jul 25, 2006
Filed:
Jul 10, 1998
Appl. No.:
09/462543
Inventors:
John K. Rose - Guilford CT, US
Matthias Schnell - Harleysville PA, US
E. Erik Johnson - New Haven CT, US
Matthias Schnell - Harleysville PA, US
E. Erik Johnson - New Haven CT, US
Assignee:
Yale University - New Haven CT
International Classification:
A61K 39/21
US Classification:
4241991, 4242021, 4242241, 4353201
Abstract:
Replication-competent recombinant rhabdoviruses that lack a functional glycoprotein gene and express at least one foreign polypeptide such as a celluar receptor for another virus in their viral envelopes are useful in the treatment of pathogenic viruses. In one embodiment, a recombinant vesicular stomatitis virus (VSV) lacking its glycoprotein (G) gene and expressing instead the HIV receptor and a coreceptor is employed in a method for treating persons infected with HIV. The recombinant virus is defective for entry into normal cells but is able to control HIV infection in a T cell line by replicating in, and killing, HIV-infected cells.
Recombinant Vesiculoviruses And Their Uses
US Patent:
2005023, Oct 27, 2005
Filed:
Nov 9, 2004
Appl. No.:
10/984414
Inventors:
John Rose - Guilford CT, US
International Classification:
A61K039/12, C12N007/00, C12N015/86
US Classification:
424199100, 435456000, 435235100
Abstract:
The present invention provides recombinant replicable vesiculoviruses. The invention provides a method which, for the first time, successfully allows the production and recovery of replicable vesiculoviruses, as well as recombinant replicable vesiculoviruses, from cloned DNA, by a method comprising expression of the full-length positive-strand vesiculovirus antigenomic RNA in host cells. The recombinant vesiculoviruses do not cause serious pathology in humans, can be obtained in high titers, and have use as vaccines. The recombinant vesiculoviruses can also be inactivated for use as killed vaccines.
Viral Vaccine Vectors
US Patent:
2010032, Dec 23, 2010
Filed:
Jan 12, 2009
Appl. No.:
12/747591
Inventors:
John K. Rose - Guilford CT, US
International Classification:
A61K 39/12, A61K 31/7088, C12N 15/63, C12N 5/10, A61P 37/04, A61P 31/12
US Classification:
4242041, 514 44 R, 4353201, 435325
Abstract:
The present invention relates to a hybrid-viral vector system, in particular, but not exclusively, to a hybrid-viral vector system that can be used as a vaccine vector.